<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title> Mesalamine (5‐ASA) for the prevention of recurrent diverticulitis - Carter, F - 2017 | Cochrane Library</title> <meta content=" Mesalamine (5‐ASA) for the prevention of recurrent diverticulitis - Carter, F - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009839.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content=" Mesalamine (5‐ASA) for the prevention of recurrent diverticulitis - Carter, F - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009839.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009839.pub2" name="dc.identifier" scheme="DOI"/> <meta content=" Mesalamine (5‐ASA) for the prevention of recurrent diverticulitis" name="citation_title"/> <meta content="Flloyd Carter" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="flloydcarter@hotmail.com" name="citation_author_email"/> <meta content="Majd Alsayb" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="John K Marshall" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Yuhong Yuan" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD009839.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/10/03" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009839.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009839.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009839.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Secondary Prevention; Anti‐Inflammatory Agents, Non‐Steroidal [adverse effects, *therapeutic use]; Diverticulitis, Colonic [*prevention &amp; control]; Mesalamine [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009839.pub2&amp;doi=10.1002/14651858.CD009839.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ytRBD0EW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009839\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009839\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009839.pub2",title:"\\n Mesalamine (5\\u2010ASA) for the prevention of recurrent diverticulitis",firstPublishedDate:"Oct 3, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Colorectal Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009839.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009839.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009839.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009839.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009839.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009839.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009839.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009839.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009839.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009839.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4444 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009839.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-sec-0078"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-sec-0070"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/appendices#CD009839-sec-0083"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/table_n/CD009839StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/table_n/CD009839StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en"> Mesalamine (5‐ASA) for the prevention of recurrent diverticulitis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/information#CD009839-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Flloyd Carter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/information#CD009839-cr-0003">Majd Alsayb</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/information#CD009839-cr-0004">John K Marshall</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009839.pub2/information#CD009839-cr-0005">Yuhong Yuan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/information/en#CD009839-sec-0089">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 03 October 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009839.pub2">https://doi.org/10.1002/14651858.CD009839.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009839-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009839-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009839-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009839-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009839-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009839-abs-0001" lang="en"> <section id="CD009839-sec-0001"> <h3 class="title" id="CD009839-sec-0001">Background</h3> <p>Diverticular disease is a common condition that increases in prevalence with age. Recent theories on the pathogenesis of diverticular inflammation have implicated chronic inflammation similar to that seen in ulcerative colitis. Mesalamine, or 5‐aminosalicylic acid (5‐ASA), is a mainstay of therapy for individuals with ulcerative colitis. Accordingly, 5‐ASA has been studied for prevention of recurrent diverticulitis. </p> </section> <section id="CD009839-sec-0002"> <h3 class="title" id="CD009839-sec-0002">Objectives</h3> <p>To evaluate the efficacy of mesalamine (5‐ASA) for prevention of recurrent diverticulitis.</p> </section> <section id="CD009839-sec-0003"> <h3 class="title" id="CD009839-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 8), in the Cochrane Library; Ovid MEDLINE (from 1950 to 9 September 2017); Ovid Embase (from 1974 to 9 September 2017); and two clinical trials registries for ongoing trials ‐ Clinicaltrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform database (9 September 2017).<br/> We also searched proceedings from major gastrointestinal conferences ‐ Digestive Disease Week (DDW), United European Gastroenterology Week (UEGW), and the American College of Gastroenterology (ACG) Annual Scientific Meeting ‐ from 2010 to September 2017. In addition, we scanned reference lists from eligible publications, and we contacted corresponding authors to ask about additional trials. </p> </section> <section id="CD009839-sec-0004"> <h3 class="title" id="CD009839-sec-0004">Selection criteria</h3> <p>We included randomised controlled clinical trials comparing the efficacy of 5‐ASA versus placebo or another active drug for prevention of recurrent diverticulitis. </p> </section> <section id="CD009839-sec-0005"> <h3 class="title" id="CD009839-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures as defined by Cochrane. Three review authors assessed eligibility for inclusion. Two review authors selected studies, extracted data, and assessed methodological quality independently. We calculated risk ratios (RRs) for prevention of diverticulitis recurrence using an intention‐to‐treat principle and random‐effects models. We assessed heterogeneity using criteria for Chi<sup>2</sup> (P &lt; 0.10) and I<sup>2</sup> tests (&gt; 50%). To explore sources of heterogeneity, we conducted a priori subgroup analyses. To assess the robustness of our results, we carried out sensitivity analyses using different summary statistics (RR vs odds ratio (OR)) and meta‐analytical models (fixed‐effect vs random‐effects). </p> </section> <section id="CD009839-sec-0006"> <h3 class="title" id="CD009839-sec-0006">Main results</h3> <p>We included in this review seven studies with a total of 1805 participants.<br/> <br/> We judged all seven studies to have unclear or high risk of bias. Investigators found no evidence of an effect when comparing 5‐ASA versus control for prevention of recurrent diverticulitis (31.3% vs 29.8%; RR 0.69, 95% confidence interval (CI) 0.43 to 1.09); very low quality of evidence). </p> <p>Five of the seven studies provided data on adverse events of 5‐ASA therapy. The most commonly reported side effects were gastrointestinal symptoms (epigastric pain, nausea, and diarrhoea). No significant difference was seen between 5‐ASA and control (67.8% vs 64.6%; RR 0.98, 95% CI 0.91 to 1.06; P = 0.63; moderate quality of evidence), nor was significant heterogeneity observed (I<sup>2</sup> = 0%; P = 0.50). </p> </section> <section id="CD009839-sec-0007"> <h3 class="title" id="CD009839-sec-0007">Authors' conclusions</h3> <p>The effects of 5‐ASA on recurrence of diverticulitis are uncertain owing to the small number of heterogenous trials included in this review. Rates of recurrent diverticulitis were similar among participants using 5‐ASA and control participants. Effective medical strategies for prevention of recurrent diverticulitis are needed, and further randomised, double‐blinded, placebo‐controlled trials of rigorous design are warranted to specify the effects of 5‐ASA (mesalamine) in the management of diverticulitis. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009839-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009839-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009839-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009839-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009839-abs-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009839-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009839-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009839-abs-0003" lang="en"> <h3>Does 5‐ASA prevent the recurrence of diverticulitis?</h3> <p><b>Background</b> </p> <p>Diverticula are small bulging pouches that can form in the lining of the digestive system, particularly in the colon. Diverticulitis is inflammation of these pouches, and it is an important complication of diverticular disease. Approximately one‐third to one‐quarter of patients who recover from one episode of diverticulitis will experience recurrence. The inflammation underlying diverticulitis may be similar to that seen in inflammatory bowel disease. 5‐Aminosalicylic acid (5‐ASA) is an anti‐inflammatory drug that has proved effective as treatment for ulcerative colitis and therefore may be useful for prevention of recurrent diverticulitis </p> <p><b>Objectives</b> </p> <p>We aimed to evaluate whether 5‐ASA prevented recurrence of diverticulitis.</p> <p><b>Study characteristics</b> </p> <p>A review of the literature identified seven studies with a total of 1805 participants for analysis. A search of the literature was conducted on 9 September 2017. These trials assigned participants with a diagnosis of diverticulitis to receive 5‐ASA or an alternative therapy. Four trials compared 5‐ASA versus placebo; one compared 5‐ASA plus probiotic versus probiotic; one compared 5‐ASA plus antibiotic versus antibiotic; and one compared 5‐ASA versus no therapy. Participants were followed to compare the recurrence rate of diverticulitis and side effects among treatment arms. </p> <p><b>Key findings</b> </p> <p>Our analysis determined that approximately one‐third of participants receiving 5‐ASA had recurrence of diverticulitis (31.3%). Participants receiving non‐5‐ASA therapy experienced a similar rate of recurrence (29.8%). Adverse event rates were similar among 5‐ASA therapy and comparison therapies. The most commonly reported side effects of 5‐ASA therapy were gastrointestinal symptoms (epigastric pain, nausea, and diarrhoea). </p> <p><b>Quality of the evidence</b> </p> <p>Overall, the quality of evidence available for analysis of recurrence of diverticulitis is considered to be very low. None of the included studies was considered to have low risk of bias for all criteria. These trials were designed differently. For example, some studies required a CT scan for diagnosis of diverticulitis, and others relied on less reliable clinical and laboratory criteria. Comparison therapies varied, with some studies using placebo, and others using antibiotics and probiotics. Although we combined the findings of these studies in our analysis, these different comparison arms made direct comparisons problematic. The confidence interval does not exclude an appreciable benefit or no difference. </p> <p>Overall, the quality of evidence available for analysis of adverse effects was moderate. Two of the included studies provided no usable data. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009839-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009839-sec-0078"></div> <h3 class="title" id="CD009839-sec-0079">Implications for practice</h3> <section id="CD009839-sec-0079"> <p>The efficacy of 5‐aminosalicylic acid (5‐ASA) for prevention of recurrence of diverticulitis is uncertain owing to the very low quality of available evidence. Accordingly, we recommend no change in practice. </p> </section> <h3 class="title" id="CD009839-sec-0080">Implications for research</h3> <section id="CD009839-sec-0080"> <p>Additional trials of rigorous design are needed to explore whether 5‐ASA is effective for prevention of recurrence of diverticulitis. Such trials should use standardised criteria to diagnosis diverticulitis, and should follow a randomised, double‐blind, placebo‐controlled design with adequate statistical power. The research design should also allow for comparison of significant complications of diverticulitis including but not exclusive to surgery for diverticulitis, colonic stenosis, abscess, and diverticular bleeding. The research design should allow for comparison of common and rare adverse events and should compare dosages and schedules. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009839-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009839-sec-0022"></div> <div class="table" id="CD009839-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">5‐ASA compared with control (all trials) for prevention of recurrent diverticulitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>5‐ASA compared with control (all trials) for prevention of recurrent diverticulitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with the need for management of diverticulitis<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> 5‐ASA<br/> <b>Comparison:</b> placebo, probiotic, antibiotic </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control (all trials)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of diverticulitis<br/> Follow‐up: range 1 to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.69<br/> (0.43 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1805<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 100<br/> (13 to 33) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events (epigastric pain, nausea, diarrhoea)<br/> Follow‐up: range 1 to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/> (0.91 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1421<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 100<br/> (59 to 68) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> 5‐ASA: 5‐aminosalicylic acid; CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (four of seven studies were assessed to be at high risk of bias). </p> <p><sup>b</sup>The confidence interval does not exclude an appreciable benefit or no difference. </p> <p><sup>c</sup>Downgraded one level for inconsistency (significant heterogeneity of results might be explained by control regimens and methods of diagnosis). </p> <p><sup>d</sup>The confidence interval excludes appreciable benefit or harm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009839-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009839-sec-0023"></div> <section id="CD009839-sec-0024"> <h3 class="title" id="CD009839-sec-0024">Description of the condition</h3> <p>Diverticular disease is common in developed countries, and its prevalence increases with age. More than 50% of people over the age of 80 have colonic diverticula (<a href="./references#CD009839-bbs2-0046" title="ParksTG . Natural history of diverticular disease of the colon. Clinical Gastroenterology1975;4:53‐69. ">Parks 1975</a>; <a href="./references#CD009839-bbs2-0024" title="BarrosoAO , QuigleyEM . Diverticula and diverticulitis: time for a reappraisal. Journal of Gastroenterology and Hepatology2015;11(10):680‐8. ">Barroso 2015</a>). Diverticulitis is the most common clinical manifestation of diverticulosis. Diverticulitis is defined as inflammation, infection, or both, associated with colonic diverticula (<a href="./references#CD009839-bbs2-0044" title="PainterNS , BurkittDP . Diverticular disease of the colon: a deficiency disease of western civilization. British Medical Journal1971;2:450‐4. ">Painter 1971</a>; <a href="./references#CD009839-bbs2-0046" title="ParksTG . Natural history of diverticular disease of the colon. Clinical Gastroenterology1975;4:53‐69. ">Parks 1975</a>; <a href="./references#CD009839-bbs2-0026" title="BuchsNC , MortensenNJ , RisF , MorelP , GervazP . Natural history of uncomplicated sigmoid diverticulitis. World Journal of Gastrointestinal Surgery2015;7(11):313‐8. ">Buchs 2015</a>). Common clinical manifestations include abdominal pain, altered bowel habits, fever. and leukocytosis, which have a considerable impact on the well‐being of patients (<a href="./references#CD009839-bbs2-0037" title="HumesDJ , SimpsonJ , NealKR , ScholefieldJH , SpillerRC . Psychological and colonic factors in painful diverticulosis. British Journal of Surgery2008;95:195‐8. ">Humes 2008</a>; <a href="./references#CD009839-bbs2-0056" title="StrateL , ModiR , CohenE , SpiegelB . Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. American Journal of Gastroenterology2012;107:1486‐93. ">Strate 2012</a>). Recurrent diverticulitis is an important clinical outcome, with reported rates ranging from as low as 7% to as high as 62% (<a href="./references#CD009839-bbs2-0047" title="PeeryA , SandlerR . Diverticular disease. Clinical Gastroenterology and Hepatology2013;11(12):1532‐7. ">Peery 2013</a>). However, the best accepted estimate of recurrence risk is one‐third to one‐quarter of patients (<a href="./references#CD009839-bbs2-0045" title="ParksTG , ConnellAM . The outcome in 455 patients admitted for treatment of diverticular disease of the colon. British Journal of Surgery1970;57:775‐8. ">Parks 1970</a>; <a href="./references#CD009839-bbs2-0055" title="StollmanN , RaskinJ . Practice guidelines: diagnosis and management of diverticular disease of the colon in adults. American Jounal of Gastroenterology1999;94(11):3110‐21. ">Stollman 1999</a>; <a href="./references#CD009839-bbs2-0029" title="ChautemsRC , AmbrosettiP , LudwigA , MermillodB , MorrelP , SoraviaC . Long term follow up after first acute episode of sigmoid diverticulitis: is surgery mandatory? A prospective study of 188 patients. Diseases of the Colon and Rectum2002;45:962‐6. ">Chautems 2002</a>; <a href="./references#CD009839-bbs2-0042" title="MorrisAM , RegenbodenSE , HardimanKM , HendrenS . Sigmoid diverticulitis: a systematic review. Journal of the American Medical Association2014;311(3):287‐97. ">Morris 2014</a>). </p> <p>No clinical classification of diverticular disease has been universally accepted. Literature is replete with terms of unclear significance. We present our definition of terms to avoid confusion. 'Diverticulosis' is merely the presence of diverticula. 'Diverticular disease' is clinically significant and symptomatic diverticulosis. DIverticular disease may occur in the form of 'diverticulitis' or 'symptomatic uncomplicated diverticular disease' (SUDD) (<a href="./references#CD009839-bbs2-0056" title="StrateL , ModiR , CohenE , SpiegelB . Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. American Journal of Gastroenterology2012;107:1486‐93. ">Strate 2012</a>). The term 'complicated diverticulitis', in this review, refers to the presence of abscess, obstruction, or purulent or faecal peritonitis (<a href="./references#CD009839-bbs2-0057" title="SzojdaMM , CuestaMA , MulderCM , Felt‐BersmaRJ . Review article: management of diverticulitis. Alimentary, Pharmacology &amp; Therapeutics2007;26(Suppl 2):67‐76. ">Szojda 2007</a>). Some investigators have described an acute and chronic diverticulitis, with chronic referring to recurrent diverticulitis or the presence of segmental colitis associated with diverticulosis syndrome (SCAD), which is an inflammatory process that affects colonic luminal mucosa in segments that are also affected by diverticulosis (<a href="./references#CD009839-bbs2-0056" title="StrateL , ModiR , CohenE , SpiegelB . Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. American Journal of Gastroenterology2012;107:1486‐93. ">Strate 2012</a>). However, this classification is not universally accepted and is not used in this review. </p> </section> <section id="CD009839-sec-0025"> <h3 class="title" id="CD009839-sec-0025">Description of the intervention</h3> <p>Mesalamine, or 5‐ASA, is used mainly for treatment of individuals with ulcerative colitis, and is believed to control inflammation through several mechanisms including inhibition of nuclear factor‐kappa B (NF‐KB). Study authors have observed that colonic diverticular disease is often associated with chronic low‐grade inflammation (<a href="./references#CD009839-bbs2-0036" title="HorganAF , McConnellEJ , WolffBG . Atypical diverticular disease: surgical results. Diseases of the Colon &amp; Rectum2001;44:1315‐6. ">Horgan 2001</a>; <a href="./references#CD009839-bbs2-0032" title="FlochMH . A hypothesis: is diverticulitis a type of inflammatory bowel disease?. Journal of Clinical Gastroenterology2006;40(Suppl 3):121‐5. ">Floch 2006</a>; <a href="./references#CD009839-bbs2-0059" title="TursiA , BrandimarteG , EliseiW , GiorgettiGM , InchingoloCD , DaneseS , et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. Journal of Clinical Gastroenterology2008;42(6):699‐703. ">Tursi 2008</a>). These observations have led to the hypothesis that 5‐ASA may also be beneficial in the management of diverticulitis. </p> <p>Treatment with 5‐ASA is generally well tolerated but can be associated with mild to serious adverse effects. The most common side effects include headache, malaise, abdominal cramping, diarrhoea, and gas. Less common effects include hair loss, skin rash, diarrhoea, and worsening of inflammation of the colon (colitis). However, to the review authors' knowledge, no reports have described worsening inflammation when 5‐ASA was used in cases of diverticulitis. Rare but serious adverse effects include pancreatitis, pneumonitis, pericarditis, and interstitial nephritis (<a href="./references#CD009839-bbs2-0050" title="RansfordRA , LangmanMJ . Sulphasalazine and mesalazine: serious adverse reactions re‐evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut2002;51(4):536‐9. ">Ransford 2002</a>; <a href="./references#CD009839-bbs2-0038" title="KaragozianR , BurakoffR . The role of mesalamine in the treatment of ulcerative colitis. Therapeutics and Clinical Risk Management2007;3(5):893‐903. ">Karagozian 2007</a>). </p> </section> <section id="CD009839-sec-0026"> <h3 class="title" id="CD009839-sec-0026">How the intervention might work</h3> <p>The pathogenesis of diverticulitis remains uncertain. A prevailing hypothesis is that obstruction of the neck of the diverticulum by inspissated stool or a fecalith leads to low‐grade inflammation and stasis within a diverticulum (<a href="./references#CD009839-bbs2-0025" title="BermanLG , BurdickD , HeitzmanER , PriorJT . A critical reappraisal of sigmoid peridiverticulitis. Surgery, Gynecology &amp; Obstetrics1968;127:481‐91. ">Berman 1968</a>; <a href="./references#CD009839-bbs2-0063" title="WilliamsRA , DavisIP . DIverticular disease of the colon. In: HaubrichWS , SchaffnerF editor(s). Brockus Gastroenterology. 5th Edition. Philadelphia: WB Saunders, 1995:1637‐56. ">Williams 1995</a>). The resulting micro‐environment favours bacterial overgrowth and leads to diminished venous outflow and local ischaemia (<a href="./references#CD009839-bbs2-0039" title="KohlerL , SauerlandS , NeugubauerE . Diagnosis and treatment of diverticular disease: results of a consensus development conference. Surgical Endoscopy1999;13:430‐6. ">Kohler 1999</a>). Obstruction, infection, and ischaemia promote active mucosal inflammation that manifests as diverticulitis. Microperforation of an inflamed diverticulum can occur, and can remain localised (as a phlegmon or pericolic or pelvic abscess) or lead to purulent or faecal peritonitis. </p> <p>It has been suggested that some of the mechanisms that underlie inflammation in diverticulitis are similar to those seen in inflammatory bowel disease (IBD) (<a href="./references#CD009839-bbs2-0048" title="PeppercornMA . The overlap of inflammatory bowel disease and diverticular disease. Journal of Clinical Gastroenterology2004;38(Suppl 5):8‐10. ">Peppercorn 2004</a>; <a href="./references#CD009839-bbs2-0032" title="FlochMH . A hypothesis: is diverticulitis a type of inflammatory bowel disease?. Journal of Clinical Gastroenterology2006;40(Suppl 3):121‐5. ">Floch 2006</a>; <a href="./references#CD009839-bbs2-0053" title="ShethAA , LongoW , FlochMH . Diverticular disease and diverticulitis. American Journal of Gastroenterology2008;103:1550‐6. ">Sheth 2008</a>). These entities appear to converge in a condition known as segmental colitis associated with diverticulosis syndrome (SCAD) (<a href="./references#CD009839-bbs2-0056" title="StrateL , ModiR , CohenE , SpiegelB . Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. American Journal of Gastroenterology2012;107:1486‐93. ">Strate 2012</a>). Individuals with SCAD have a chronic inflammation that resembles IBD and has no known cause (<a href="./references#CD009839-bbs2-0034" title="GoldsteinNS , Leon‐ArminC , ManiA . Crohn's colitis‐like change in sigmoid diverticulitis specimens is usually an idiosyncratic inflammatory response to the diverticulosis rather than Crohn's colitis. Americal Journal of Surgical Pathology2000;24:668. ">Goldstein 2000</a>; <a href="./references#CD009839-bbs2-0033" title="FreemanNJ . Natural history and long‐term clinical behaviour of segmental colitis associated with diverticulosis (SCAD syndrome). Digestive Disease Science2008;53:2452‐7. ">Freeman 2008</a>). </p> <p>5‐ASA has anti‐inflammatory and immunosuppressive effects (<a href="./references#CD009839-bbs2-0043" title="NielsenOH , MunckLK . Drug Insight: aminosalicylates for the treatment of IBD. Nature Clinical Practice Gastroenterology and Hepatology2007;4:160‐70. ">Nielsen 2007</a>). It has been hypothesised that 5‐ASA may also modulate inflammation in diverticulitis and reduce the frequency of recurrent attacks (<a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>; <a href="./references#CD009839-bbs2-0031" title="DiMarioF , ComparatoG , Fanigliulo L. CavallaroLG , CavestroGM , et al. Use of mesalazine in diverticular disease. Journal of Clinical Gastroenterology2006;40(Suppl 3):S155‐9. ">Di Mario 2006</a>). </p> </section> <section id="CD009839-sec-0027"> <h3 class="title" id="CD009839-sec-0027">Why it is important to do this review</h3> <p>It is estimated that between 15% and 25% of patients with diverticulosis will experience an episode of diverticulitis (<a href="./references#CD009839-bbs2-0046" title="ParksTG . Natural history of diverticular disease of the colon. Clinical Gastroenterology1975;4:53‐69. ">Parks 1975</a>; <a href="./references#CD009839-bbs2-0055" title="StollmanN , RaskinJ . Practice guidelines: diagnosis and management of diverticular disease of the colon in adults. American Jounal of Gastroenterology1999;94(11):3110‐21. ">Stollman 1999</a>). Between 15% and 30% of those admitted with diverticulitis will require surgery during that admission (<a href="./references#CD009839-bbs2-0046" title="ParksTG . Natural history of diverticular disease of the colon. Clinical Gastroenterology1975;4:53‐69. ">Parks 1975</a>), and approximately one‐third will experience recurrent episodes of diverticulitis (<a href="./references#CD009839-bbs2-0055" title="StollmanN , RaskinJ . Practice guidelines: diagnosis and management of diverticular disease of the colon in adults. American Jounal of Gastroenterology1999;94(11):3110‐21. ">Stollman 1999</a>; <a href="./references#CD009839-bbs2-0029" title="ChautemsRC , AmbrosettiP , LudwigA , MermillodB , MorrelP , SoraviaC . Long term follow up after first acute episode of sigmoid diverticulitis: is surgery mandatory? A prospective study of 188 patients. Diseases of the Colon and Rectum2002;45:962‐6. ">Chautems 2002</a>). Recent studies have found lower recurrence rates of around 16% (<a href="./references#CD009839-bbs2-0026" title="BuchsNC , MortensenNJ , RisF , MorelP , GervazP . Natural history of uncomplicated sigmoid diverticulitis. World Journal of Gastrointestinal Surgery2015;7(11):313‐8. ">Buchs 2015</a>). Diverticulitis and disease‐related complications can be associated with significant morbidity and a negative impact on quality of life.<br/> <br/> We have performed a systematic review of the literature to assess the efficacy of 5‐ASA in the management of diverticulitis relative to other active therapies and placebo. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009839-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009839-sec-0028"></div> <p>To evaluate the efficacy of 5‐ASA (mesalamine) for prevention of recurrent diverticulitis.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009839-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009839-sec-0029"></div> <section id="CD009839-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009839-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled clinical trials (including cluster and cross‐over randomised controlled trials (RCTs)) comparing the efficacy of 5‐ASA versus control (placebo, no treatment, or another active drug) for prevention of recurrent diverticulitis. </p> </section> <section id="CD009839-sec-0032"> <h4 class="title">Types of participants</h4> <p>Participants older than 18 years of age, with diverticulitis diagnosed by endoscopy, radiology, and/or clinical symptoms. </p> </section> <section id="CD009839-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Administration of 5‐ASA, orally or rectally and at any dose, to at least one treatment arm. Comparators could include placebo or another active medical therapy. </p> </section> <section id="CD009839-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD009839-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009839-list-0001"> <li> <p>Rate of recurrence of diverticulitis</p> </li> </ul> </p> <p>Recurrent diverticulitis is diagnosed mainly on clinical grounds with support of laboratory, endoscopic, and radiological investigations. A computerised tomography (CT) scan is preferred for diagnosis but is not required by our protocol for selection. We accepted the diagnostic criteria of the investigators for this outcome. </p> </section> <section id="CD009839-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009839-list-0002"> <li> <p>Adverse effects of therapy</p> </li> </ul> </p> <p>Any reported adverse events are eligible. Because of anticipated heterogeneity in the definition of these outcomes, we accepted those of the original study authors. </p> </section> </section> </section> <section id="CD009839-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We designed search strategies by using a combination of subject headings and text words related to 5‐ASA and diverticulitis. </p> <section id="CD009839-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We conducted a comprehensive literature search to identify all published and unpublished RCTs with no language restriction. We searched the following electronic databases to identify potential studies. </p> <p> <ul id="CD009839-list-0003"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 8), in the Cochrane Library (<a href="./appendices#CD009839-sec-0084">Appendix 1</a>). </p> </li> <li> <p>Ovid MEDLINE and MEDLINE In‐Process &amp; Other Non‐Indexed Citations (Ovid) 1946 to 9 September 2017 (<a href="./appendices#CD009839-sec-0085">Appendix 2</a>). </p> </li> <li> <p>Ovid Embase 1974 to 9 September 2017 (<a href="./appendices#CD009839-sec-0086">Appendix 3</a>). </p> </li> </ul> </p> <p>We did not apply the standard Cochrane search strategy filter for RCTs because we identified a relatively small number of hits during searches of MEDLINE and Embase.     </p> </section> <section id="CD009839-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We searched the following clinical trials registries on 9 September 2017, for protocols for ongoing trials. </p> <p> <ul id="CD009839-list-0004"> <li> <p>Clinical trials.gov.</p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform search portal (http://www.who.int/ictrp/en/)<i>.</i> </p> </li> </ul> </p> <p>We handsearched abstracts in conference proceedings from Digestive Disease Week (published in <i>Gastroenterology</i> and<i>Gastrointestinal Endoscopy</i> ), United European Gastroenterology Week (published in <i>Gut</i> ), and the American College of Gastroenterology Annual Scientific Meeting (published in <i>American Journal of Gastroenterology</i>) (2010 to 2017).<br/> <br/> We scanned reference lists from retrieved articles to identify additional citations that may have been overlooked during the database search. </p> </section> </section> <section id="CD009839-sec-0040"> <h3 class="title" id="CD009839-sec-0040">Data collection and analysis</h3> <section id="CD009839-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (FC, MA) independently screened citations for peer‐reviewed papers identified by the above search strategies for potential relevance. We obtained full texts for potentially relevant citations. Two review authors (of FC, MA, and YY) then independently reviewed these citations for inclusion in the review by applying four criteria. </p> <p> <ul id="CD009839-list-0005"> <li> <p>Confirmed diverticulitis diagnosed by endoscopy, radiology, and/or clinical symptoms.</p> </li> <li> <p>5‐ASA administered to at least one treatment arm (at randomisation).</p> </li> <li> <p>Treatment allocation randomised or quasi‐randomised.</p> </li> <li> <p>Symptomatic recurrence of diverticulitis as a measured outcome.</p> </li> </ul> </p> <p>Each investigator rated each criterion on a three‐point scale: yes, no, or not stated. Studies with a 'yes' for all four criteria were eligible for inclusion. A third review author resolved disagreements. </p> </section> <section id="CD009839-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two independent review authors (of FC, MA, and YY) used a standardised form to extract prespecified data from eligible studies. When necessary, we contacted authors of the original studies for clarification of data, additional information, or both. Extracted data included the following. </p> <p> <ul id="CD009839-list-0006"> <li> <p>Numbers of participants enrolled and allocated to each treatment arm.</p> </li> <li> <p>Participant characteristics (age, gender).</p> </li> <li> <p>Type of intervention administered in each treatment arm (dose, formulation, frequency, duration). </p> </li> <li> <p>Numbers of participants in each treatment arm in symptomatic remission and with recurrent diverticulitis. </p> </li> <li> <p>Numbers, nature, and severity of reported adverse events in each treatment arm.</p> </li> <li> <p>Number of participants in each arm lost to follow‐up or dropout.</p> </li> <li> <p>Study definitions of recurrent diverticulitis and symptom remission.</p> </li> </ul> </p> </section> <section id="CD009839-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Review authors assessed risk of bias using the Cochrane tool for risk of bias assessment (<a href="./references#CD009839-bbs2-0035" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: HigginsJP , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>). This tool measures factors that impact the quality of a trial, including the following domains. </p> <p> <ul id="CD009839-list-0007"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective reporting.</p> </li> <li> <p>Other risk of bias (such as baseline imbalance, blocked randomisation in unblinded trials, conduct of the study affected by interim results, etc.). </p> </li> </ul> </p> <p>We assessed risk of bias domains as having high, unclear, or low risk of bias using the 'Risk of bias' tool (see <a href="./appendices#CD009839-sec-0087">Appendix 4</a>; <a href="./references#CD009839-bbs2-0035" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: HigginsJP , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>). We summarised risk of bias for the primary outcome within a study across all domains. We considered a study to have “high risk of bias” when we judged risk of bias as high for one or more domains; “low risk of bias” only when we judged risk of bias as low for all domains; and "unclear risk of bias" when reporting did not permit judgement of high or low risk. We also reported any other important concerns that we had about bias identified in the studies. </p> </section> <section id="CD009839-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We performed statistical analysis according to the study classification presented above. We calculated the pooled risk ratio (RR) and corresponding 95% confidence intervals (CIs) for recurrent diverticulitis, and we calculated the number of participants with adverse events. We did not calculate a pooled RR for individual adverse events because data were insufficient. </p> </section> <section id="CD009839-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We included in this review trials that randomised participants to 5‐ASA versus control. We did not identify any cluster‐randomised or cross‐over trials for inclusion in this review. Thus, the unit of analysis is the individual participant. </p> </section> <section id="CD009839-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact study authors to ask for missing data. If no outcome data were available, we used the intention‐to‐treat (ITT) approach to analyse all randomised participants according to their treatment assignments. We used a conservative approach and presumed that missing participants had failed treatment (worst‐case scenario). </p> </section> <section id="CD009839-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity using the Chi<sup>2</sup> test (P &lt; 0.10 indicates significant heterogeneity) and the I<sup>2</sup> statistic (&gt; 50% indicates substantial heterogeneity) and a random‐effects model, along with visual inspection of forest plots. When we found significant or substantial heterogeneity, we investigated possible explanations by performing subgroup analyses. Potential sources of heterogeneity hypothesised a priori include the following. </p> <p> <ul id="CD009839-list-0008"> <li> <p>Control regimens (5‐ASA + probiotics vs probiotics, 5‐ASA + antibiotics vs antibiotics, 5‐ASA vs placebo, 5‐ASA vs no treatment, and 5‐ASA + probiotics vs placebo). </p> </li> <li> <p>Method of diagnosis (diverticulitis confirmed by CT scan/ultrasonography vs others).</p> </li> <li> <p>Risk of bias (low vs unclear and high).</p> </li> <li> <p>Publication type (abstract vs full text).</p> </li> </ul> </p> <p>We did not exclude studies or abstracts at high risk of bias; instead, we reported pooled estimates for both subgroups along with tests of subgroup differences. We reported data for two risk of bias subgroups and planned to explore whether risk of bias explains the heterogeneity (e.g. sometimes studies at high risk of bias can explain heterogeneity). </p> </section> <section id="CD009839-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess small‐study effects or publication bias by examining the relationship between treatment effects and standard error of the estimate using a funnel plot (<a href="./references#CD009839-bbs2-0054" title="SterneJ , EggerM , MoherD , on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting bias. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Sterne 2011</a>). The general recommendation is that a funnel plot should be included only if the meta‐analysis includes 10 or more studies. Because only seven studies were eligible, we did not assess publication bias in this systematic review. </p> </section> <section id="CD009839-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We performed and presented meta‐analysis of outcomes for the comparison of 5‐ASA versus control. We performed meta‐analysis only if we identified two or more trials with similar comparisons and outcome measures. We calculated a pooled risk ratio (RR) using a random‐effects model (Mantel‐Haenszel), as both outcomes were dichotomous. When studies reported repeated observations, we analysed data measured at the last follow‐up time point. When studies allocated participants to more than one 5‐ASA treatment arm, we combined these studies for the primary analysis. </p> </section> <section id="CD009839-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analyses for subgroups for primary outcomes defined by the following study‐level covariates, when reported. </p> <p> <ul id="CD009839-list-0009"> <li> <p>Control regimens (5‐ASA + probiotics vs probiotics, 5‐ASA + antibiotics vs antibiotics, 5‐ASA vs placebo, 5‐ASA vs no treatment, and 5‐ASA + probiotics vs placebo). </p> </li> <li> <p>5‐ASA dose.</p> </li> <li> <p>Participant age and gender.</p> </li> <li> <p>Number of prior episodes of diverticulitis.</p> </li> <li> <p>Method of diagnosis (diverticulitis confirmed by CT scan/ultrasonography vs other methods). </p> </li> <li> <p>Risk of bias (low vs unclear and high).</p> </li> <li> <p>Publication type (abstract vs full text).</p> </li> </ul> </p> <p>All studies were full papers; therefore insufficient study‐level data were available for 5‐ASA dose, participant age and gender, and number of prior episodes. Subgroup analyses were possible only for control regimens, methods of diagnosis, and risk of bias. </p> </section> <section id="CD009839-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We performed the following sensitivity analyses.</p> <p> <ul id="CD009839-list-0010"> <li> <p>Summary statistic (risk ratios vs odds ratios).</p> </li> <li> <p>Meta‐analysis modelling (fixed‐effect vs random‐effects).</p> </li> </ul> </p> <section id="CD009839-sec-0052"> <h5 class="title">GRADE and 'Summary of findings' table</h5> <p>We evaluated the overall quality of evidence for primary (rate of recurrence of diverticulitis) and secondary (adverse effects of therapy) outcomes using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD009839-bbs2-0052" title="SchünemannH , BrozekJ , OxmanA , editors. The GRADE Working Group, 2009 . GRADE Handbook for Grading Quality of Evidence and Strength of Recommendation. Available from http://www.cc‐ims.net/gradepro. Version 3.2 (updated March 2009). ">Schünemann 2009</a>). We presented this evaluation in a 'Summary of findings' table. </p> <p>We could downgrade evidence from high quality by one level (serious concern) or two levels (very serious concern) for the following reasons: risk of bias, inconsistency (unexplained heterogeneity, inconsistency of results), indirectness (indirect population, intervention, control, or outcomes), imprecision (wide confidence interval), and publication bias. </p> <p>We applied the following definitions in grading the quality of evidence.</p> <p> <ul id="CD009839-list-0011"> <li> <p>High quality: Further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low quality: Any estimate of effect is very uncertain.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009839-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009839-sec-0053"></div> <section id="CD009839-sec-0054"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD009839-sec-0092" title="">Characteristics of included studies</a> and <a href="./references#CD009839-sec-0093" title="">Characteristics of excluded studies</a>. </p> <section id="CD009839-sec-0055"> <h4 class="title">Results of the search</h4> <p>We identified 714 citations through the electronic database search. We identified one additional study, published only in abstract form, by searching conference proceedings (<a href="./references#CD009839-bbs2-0012" title='GamanA , TeodorescuR , GeorhescuEF , AbagiuMT . Prophylactic effects of mesalamine in diverticular disease. Falk Symposium "Diverticular disease: a fresh approach to a neglected disease". Guerzenich Congress Center, Cologne, Germany, 2011; Vol. 178:Abstract 13. '>Gaman 2011</a>). After removing duplicates, we screened 528 studies for eligibility. Of these, we excluded 505 studies because they did not meet the inclusion criteria. We found that 23 studies were eligible for inclusion. We obtained full text for 18 studies; the remaining five studies were available only in abstract form. In summary, seven studies (reported in eight references) fulfilled our inclusion criteria. For details on study selection, see PRISMA flow chart <a href="#CD009839-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD009839-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009839-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009839-sec-0056"> <h4 class="title">Included studies</h4> <p>Trespi reported 12‐month follow‐up results from a single‐centre randomised trial that compared 5‐ASA versus no therapy for prevention of complications of diverticulitis (<a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>). Diagnosis was confirmed by radiological imaging in the presence of fever, abdominal distension, or major change in bowel habit. Investigators randomised 166 participants after initial treatment with ampicillin/sulbactam 1.5 g IM twice daily plus rifaximin 400 mg PO twice daily for seven days. They randomised participants to 5‐ASA 400 mg twice daily or to no further therapy for eight weeks. After 12 months, the dropout rate was higher in the 5‐ASA group than in the control group (n = 15, 19%; vs n = 12, 14%); most cases of dropout were due to poor compliance or withdrawal of consent. After four years, 44 participants dropped out (27%). Recurrence rates were 12/81 (15%) vs 39/85 (46%) (<a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>). Study authors did not state definitive criteria for recurrent diverticulitis. However, they followed participants for relapse of symptoms and repeated blood tests at intervals to detect relapse of inflammation. Risk of bias was high because outcome data were incomplete. </p> <p>Tursi published a 12‐month RCT that compared 5‐ASA 800 mg three times daily plus rifaximin 400 mg twice daily for seven days followed by 5‐ASA 800 mg twice daily plus rifaximin 400 mg twice daily for seven days every month (n = 109) versus rifaximin 400 mg twice daily alone for seven days every month (n = 109) among 218 participants with recurrent attacks of acute colonic diverticulitis (<a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>). Researchers defined diverticulitis as inflammation and/or infection associated with diverticula of the colon and confirmed diagnosis by colonoscopy or double contrast radiography. Clinical criteria included abdominal pain, fever, and leukocytosis with elevated inflammatory markers. A total of 193 participants were fully compliant with therapy. Three participants in the 5‐ASA arm (2.8%) and 16 in the rifaximin monotherapy arm (18.0%) experienced recurrence of acute diverticulitis (P &lt; 0.005). Investigators diagnosed recurrence on the basis of clinical symptoms (abdominal pain, altered bowel habits, fever) and endoscopic examination (inflamed mucosa at endoscopy). The severity of symptoms was lower with 5‐ASA (85.6% vs 49.4%; P &lt; 0.0005 at 12 months). One participant in the 5‐ASA group developed transient urticaria (0.9%) and nine reported epigastric pain (8.3%), but treatment allocation was not reported. Therefore, we did not include this study in the analysis of adverse events. Study authors concluded that rifaximin plus 5‐ASA was more effective than rifaximin alone for prevention of recurrence of diverticulitis. </p> <p>Tursi reported a randomised single‐centre trial that compared the efficacy of 5‐ASA (balsalazide) 2.25 g/d for 10 days per month plus a probiotic mixture VSL#3 450 billion/d for 15 days per month versus the probiotic alone for 12 months for prevention of recurrent diverticulitis in 30 participants with uncomplicated diverticulitis of the colon (<a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>). Investigators defined diagnosis by the presence of symptomatic diverticula at colonoscopy with signs of inflammation but without complications. They induced remission with rifaximin 800 mg/d and 5‐ASA 2.25 g/d for 10 days. As no blinding of participants or physicians was reported, we considered this study to be at high risk of bias for "allocation concealment" and "blinding of participants and personnel". One participant in each group was lost to follow‐up (one in the 5‐ASA arm with poor compliance, and one lost to follow‐up in the control arm). In the 5‐ASA arm, one participant had recurrent diverticulitis and two experienced recurrent symptoms without diverticulitis. In the control arm, two participants experienced recurrent diverticulitis and four had recurrent symptoms without diverticulitis. Results showed no statistical significant differences between the two groups for remission rates or overall symptom scores. Symptom scores for constipation, abdominal pain, and bloating were significantly lower in the 5‐ASA group. Investigators evaluated recurrent diverticulitis on the basis of clinical symptoms (abdominal pain, altered bowel habit, fever) and/or endoscopic examination findings. They reported no adverse events in either group throughout the study. Study authors concluded that the combination of 5‐ASA and probiotic was better than probiotic monotherapy in preventing relapse of uncomplicated diverticulitis of the colon, although their findings did not reach statistical significance. </p> <p>Parente reported a randomised, multi‐centre, double‐blind, placebo‐controlled trial comparing 5‐ASA 800 mg twice daily for 10 days per month versus placebo for 24 months for preventing recurrence of diverticulitis in 96 participants (<a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>). Diagnosis of diverticulitis was based on clinical symptoms (abdominal pain, fever, leukocytosis, and increased erythrocyte sedimentation (ESR)/C‐reactive protein (CRP)) and was confirmed by abdominal ultrasonography or CT scanning. The primary endpoint recurrence of diverticulitis was diagnosed clinically in the presence of abdominal pain, leukocytosis, and/or fever. Recurrence was confirmed by cross‐sectional imaging (CT or ultrasonography). Secondary endpoints included time to relapse, physical condition, and quality of life as evaluated by the Therapeutic Impact Questionnaire (TIQ); use of additional drugs; and treatment tolerability. Four participants did not receive study drug after randomisation (treatment allocation not stated), and study authors' modified ITT analysis included only 92 participants. Sixteen participants were lost to follow‐up because of dropouts (n = 4) and serious side effects (n = 8 with 5‐ASA vs n = 4 with placebo). Therefore, we assessed this study as having high risk of bias for incomplete outcome data. After 24 months, the incidence of diverticulitis recurrence was 13.3% (n = 6) in the 5‐ASA arm and 27.7% (n = 13) in the placebo arm (difference not significant). TIQ scores for physical condition were significantly better with 5‐ASA than with placebo (P = 0.02). Global additional drug consumption was less among participants taking 5‐ASA (P &lt; 0.03). Adverse events were more common with placebo (48.9% vs 35.6%). Study authors concluded that intermittent 5‐ASA did not reduce risk of relapse but improved participants' physical condition and reduced requirements for other gastrointestinal drugs. </p> <p>Stollman reported a multi‐centre randomised, double‐blind, double‐dummy, placebo‐controlled trial conducted to assess the efficacy of 5‐ASA in reducing gastrointestinal symptoms after an acute attack of diverticulitis (<a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>). Participants received 5‐ASA (2.4 g once daily), 5‐ASA plus probiotic(<i>Bifidobacterium infantis</i> 35624), or placebo for 12 weeks, and were followed for an additional nine months. Investigators randomised 117 participants within seven days after CT imaging confirmed acute diverticulitis. They assessed efficacy using a global gastrointestinal symptomatic score (GSS) wherein the maximum severity of 10 symptoms was reported on a seven‐point Likert scale. The primary outcome was GSS at 12 weeks. Secondary outcome measures included percentage of GSS responders and change in GSS at 12 weeks and 52 weeks, withdrawal due to surgery for diverticulitis, and recurrent diverticulitis. Study authors noted that recurrent diverticulitis was diagnosed on clinical grounds, and that a CT scan was not required by the protocol. They reported a trend towards improved symptoms with 5‐ASA but reported statistical significance only for complete response rate and specific rectosigmoid symptoms. Investigators noted no statistical significant differences in rate of recurrence of diverticulitis. Subgroup analysis by regimens and controls (<a href="./references#CD009839-fig-0011" title="">Analysis 2.1</a>) split the shared placebo group into two groups with smaller sample size and included data for two subgroups, according to the Cochrane guideline (Chapter 16.5.4). In all, 9 (25%) vs 8 (20%) vs 12 (30%) participants in 5‐ASA + probiotic, 5‐ASA, and placebo groups, respectively, did not complete treatment after 12 weeks, and 12 (33%), 13 (33%), and 19 (46%) did not complete the 52‐week study. Although study authors provided reasons for withdrawal, the overall number of participants without outcome data was greater than 20%, with more withdrawals in the placebo group. Therefore, we considered this study to be at high risk of bias for incomplete outcome data. </p> <p>Raskin conducted identical multi‐centre, multi‐national, dose‐response trials (<a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>. PREVENT1 enrolled 590 participants and PREVENT2 enrolled 592 participants with one or more episodes of acute diverticulitis in the previous 24 months that resolved without surgery. Investigators confirmed diverticulitis by CT, magnetic resonance imaging (MRI), ultrasonography, colonoscopy, sigmoidoscopy, or barium enema. They randomised participants to one of three doses of 5‐ASA (1.2 g, 2.4 g, or 4.8 g) or to placebo once daily for 104 weeks. The primary endpoint was absence of recurrence by week 104. Secondary endpoints included time to recurrence of diverticulitis and proportion of participants requiring surgical intervention. This study defined recurrent diverticulitis as surgical intervention at any time for diverticular disease or a positive CT scan result. In PREVENT1, only the 5‐ASA dose of 4.8 g was associated with a lower recurrence rate than placebo (52.7% vs 64.6%; P = 0.047). PREVENT2 reported no significant difference in recurrence between any 5‐ASA dose and placebo. Study authors concluded that 5‐ASA was not superior to placebo for preventing recurrent diverticulitis. </p> <p>Of note, four of the seven included studies were conducted in Italy (<a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>; <a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>; <a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>). One was conducted in the United States (<a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>). Two were multi‐national studies (<a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). </p> </section> <section id="CD009839-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We excluded twelve studies (see table of <a href="#CD009839-sec-0057">Excluded studies</a>). Nine studies because they included participants with symptomatic uncomplicated diverticular disease but not diverticulitis (<a href="./references#CD009839-bbs2-0008" title="BrandimarteG , TursiA . Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Medical Science Monitor2004;10(5):170‐3. ">Brandimarte 2004</a>; <a href="./references#CD009839-bbs2-0015" title="MarioFD , AragonaG , LeandroG , ComparatoG , FanigliuloL , CavallaroLG , et al. Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Digestive Diseases and Sciences2005;50(3):581‐6. ">Mario 2005</a>; <a href="./references#CD009839-bbs2-0016" title="TursiA , BrandimarteG , GiorgettiGM , EliseiW . Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open‐label study. Journal of Clinical Gastroenterology2006;40(4):312‐6. ">Tursi 2006</a>; <a href="./references#CD009839-bbs2-0009" title="ComparatoG , FanigliuloL , AragonaG , CavestroGM , CavallaroLG , LeandroG , et al. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment?. Digestive Diseases2007;25(3):252‐9. ">Comparato 2007a</a>; <a href="./references#CD009839-bbs2-0010" title="ComparatoG , FanigliuloL , CavallaroLG , AragonaG , CavestroGM , IoriV , et al. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12‐month follow‐up. Digestive Diseases &amp; Sciences2007;52(11):2934‐41. ">Comparato 2007b</a>; <a href="./references#CD009839-bbs2-0017" title="TursiA , BrandimarteG , GiorgettiGM , EliseiW . Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Digestive Diseases &amp; Sciences2007;52(3):671‐4. ">Tursi 2007b</a>; <a href="./references#CD009839-bbs2-0012" title='GamanA , TeodorescuR , GeorhescuEF , AbagiuMT . Prophylactic effects of mesalamine in diverticular disease. Falk Symposium "Diverticular disease: a fresh approach to a neglected disease". Guerzenich Congress Center, Cologne, Germany, 2011; Vol. 178:Abstract 13. '>Gaman 2011</a>; <a href="./references#CD009839-bbs2-0014" title="KruisW , MeierE , SchumacherM , MickischO , GreinwaldR , MuellerR . Randomised clinical trial: mesalazine (salofalk granules) for uncomplicated diverticular disease of the colon ‐ a placebo‐controlled study. Alimentary Pharmacology and Therapeutics2013;37(7):680‐90. ">Kruis 2013a</a>; <a href="./references#CD009839-bbs2-0019" title="TursiA , BrandimarteG , EliseiW , PicchioM , FortiG , PianeseG , et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – a double‐blind, randomised, placebo‐controlled study. Alimentary Pharmacology &amp; Therapeutics2013;38(7):741‐51. ">Tursi 2013b</a>), and furthermore three studies because they were not randomised controlled trials (<a href="./references#CD009839-bbs2-0013" title="GattaL , DiMarioF , CurloM , VairaD , PilottoA , LucariniP , et al. Long‐term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease. Internal and Emergency Medicine2012;7(2):133‐7. ">Gatta 2012</a>; <a href="./references#CD009839-bbs2-0018" title="TursiA , DiMarioF , BrandimarteG , EliseiW , PicchioM , LoperfidoS , et al. Intermittent versus every‐day mesalazine therapy in preventing complications of diverticular disease: a long‐term follow‐up study. European Review for Medical and Pharmacological Sciences2013;17(23):3244‐8. ">Tursi 2013</a>; <a href="./references#CD009839-bbs2-0011" title="FestaV , PapiC , ChiesaraF , MorettiA , DeziA , BianchiM , et al. Prevention of recurrent diverticulitis: a pragmatic trial with mesalazine versus rifaximin. Digestive and Liver Disease. 21st National Congress of Digestive Diseases, Italian Federation of Societies of Digestive Diseases2015;47:e169. ">Festa 2015</a>). </p> <section id="CD009839-sec-0058"> <h5 class="title">Studies awaiting assessment</h5> <p>We could not classify four remaining studies from our searches (<a href="./references#CD009839-bbs2-0021" title="KruisW , EisenbachT , LohrH , MuserM , TanGT , LukasM , et al. Double‐blind, randomized, placebo‐controlled, multicenter trial of mesalamine for the prevention of recurrence of diverticulitis. Gastroenterology. 2013; Vol. 144 (5 Suppl 1):S139. ">Kruis 2013b</a>; <a href="./references#CD009839-bbs2-0022" title="KruisW , KardalinosV , CurtinA , DorofeyevAE , ZakkoSF , WolknerJ , et al. Daily mesalamine fails to prevent recurrent diverticulitis in a large placebo controlled multicenter trial. Digestive Disease Week. 2014; Vol. 146, issue 5 Suppl 1:S187. ">Kruis 2014</a>; <a href="./references#CD009839-bbs2-0020" title="BassiR . Preventing recurrence of symptomatic diverticular disease of the colon: mesalazine with or without Lactobacillus casei: a prospective randomized, open label study. 10th Scientific and Annual Meeting of the European Society of Coloproctology, Dublin. Ireland. 2015; Vol. 17:49‐50. ">Bassi 2015</a>; <a href="./references#CD009839-bbs2-0023" title="KruisW , KardalinosV , EisenbachT , LukasM , VichT , BuganicI , et al. Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Alimentary Pharmacology &amp;Therapeutics2017;46:282‐91. ">Kruis 2017</a>). Two were randomised, double‐blind, placebo‐controlled phase 3 studies that were available only in conference abstract form and came from the same study group. We did not include these studies because they provided insufficient data, and, unfortunately, even after three years, they had produced no full publications (<a href="./references#CD009839-bbs2-0021" title="KruisW , EisenbachT , LohrH , MuserM , TanGT , LukasM , et al. Double‐blind, randomized, placebo‐controlled, multicenter trial of mesalamine for the prevention of recurrence of diverticulitis. Gastroenterology. 2013; Vol. 144 (5 Suppl 1):S139. ">Kruis 2013b</a>; <a href="./references#CD009839-bbs2-0022" title="KruisW , KardalinosV , CurtinA , DorofeyevAE , ZakkoSF , WolknerJ , et al. Daily mesalamine fails to prevent recurrent diverticulitis in a large placebo controlled multicenter trial. Digestive Disease Week. 2014; Vol. 146, issue 5 Suppl 1:S187. ">Kruis 2014</a>). One study randomised 330 participants who had been treated successfully for uncomplicated left‐sided diverticulitis to receive 5‐ASA 1.5 g or 3 g once daily or placebo for 96 weeks. Among 164 participants assessed at 96 weeks, recurrence‐free proportions were 6.9%, 9.8%, and 21.8%, respectively (P &gt; 0.05) (<a href="./references#CD009839-bbs2-0022" title="KruisW , KardalinosV , CurtinA , DorofeyevAE , ZakkoSF , WolknerJ , et al. Daily mesalamine fails to prevent recurrent diverticulitis in a large placebo controlled multicenter trial. Digestive Disease Week. 2014; Vol. 146, issue 5 Suppl 1:S187. ">Kruis 2014</a>). A third trial randomised 345 participants with uncomplicated left‐sided diverticulitis to 5‐ASA 3 g once daily or placebo. After 48 weeks, 67.9% of participants given 5‐ASA and 74.4% of those given placebo were recurrence free (P &gt; 0.05) (<a href="./references#CD009839-bbs2-0021" title="KruisW , EisenbachT , LohrH , MuserM , TanGT , LukasM , et al. Double‐blind, randomized, placebo‐controlled, multicenter trial of mesalamine for the prevention of recurrence of diverticulitis. Gastroenterology. 2013; Vol. 144 (5 Suppl 1):S139. ">Kruis 2013b</a>). None of these trials found 5‐ASA to be significantly superior to placebo for prevention of recurrence of uncomplicated diverticulitis. We contacted study authors for further information, but they did not respond. The fourth study, which reported two randomised, double‐blind, placebo‐controlled, multi‐centre trials, is awaiting final classification (<a href="./references#CD009839-bbs2-0023" title="KruisW , KardalinosV , EisenbachT , LukasM , VichT , BuganicI , et al. Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Alimentary Pharmacology &amp;Therapeutics2017;46:282‐91. ">Kruis 2017</a>).<br/> The final excluded study was a randomised, open‐label study that also was available only in conference abstract form. We did not include this study because information was insufficient for review authors to determine whether patients with diverticulitis were included in the study. Investigators randomised 34 participants after induction of remission with metronidazole and mesalazine for 14 days. Participants received mesalazine 1.6 g once daily or mesalazine 1.6 g plus probiotic (<i>L. casei</i> DG 16 billion/d for 10 days per month). After 12 months of treatment, four participants (11.8%) were symptom free. Study authors provided no other results and concluded that both mesalazine and probiotics were effective in preventing recurrence in uncomplicated symptomatic diverticular disease of the colon (<a href="./references#CD009839-bbs2-0020" title="BassiR . Preventing recurrence of symptomatic diverticular disease of the colon: mesalazine with or without Lactobacillus casei: a prospective randomized, open label study. 10th Scientific and Annual Meeting of the European Society of Coloproctology, Dublin. Ireland. 2015; Vol. 17:49‐50. ">Bassi 2015</a>). </p> <p>We have presented these trials in the <a href="./references#CD009839-sec-0094" title="">Characteristics of studies awaiting classification</a> section. </p> </section> </section> </section> <section id="CD009839-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>We have presented results of risk of bias analysis in <a href="#CD009839-fig-0002">Figure 2</a> and <a href="#CD009839-fig-0003">Figure 3</a>. Two review authors (of FC, YY, and MA) independently assessed risk of bias of eligible trials using the Cochrane 'Risk of bias' tool (Chapter 8, <a href="./references#CD009839-bbs2-0035" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: HigginsJP , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>; <a href="./appendices#CD009839-sec-0087">Appendix 4</a>). We considered four studies as having high risk of bias, and the remaining three as having unclear risk of bias. </p> <div class="figure" id="CD009839-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009839-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009839-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009839-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009839-sec-0060"> <h4 class="title">Allocation</h4> <p>We considered three studies to have low risk of bias for random sequence generation (<a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). We considered the other four studies to have unclear risk of bias because study authors provided insufficient information.<br/> <br/> We considered only one study to have low risk of bias for allocation concealment (<a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>). The remaining studies did not provide sufficient information. </p> </section> <section id="CD009839-sec-0061"> <h4 class="title">Blinding</h4> <p>Four studies were double‐blinded (<a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). One study was an open‐label study; therefore we considered it to have high risk of bias for participants and personnel (<a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>). The other studies did not report methods of blinding.<br/> <br/> Only three studies clearly stated that outcome assessors were blinded (<a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). We considered the other studies to have unclear risk of bias for outcome assessment. </p> </section> <section id="CD009839-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies had high risk of bias for the domain "incomplete outcome data" (<a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>; <a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>). We have discussed details under <a href="./references#CD009839-sec-0092" title="">Characteristics of included studies</a>. </p> </section> <section id="CD009839-sec-0063"> <h4 class="title">Selective reporting</h4> <p>Five studies reported all important outcomes; we therefore considered them to have low risk of bias for selective reporting. We considered two studies to have unclear risk for selective reporting because study authors did not clearly report data on adverse events (<a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>; <a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>). </p> </section> <section id="CD009839-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p>We considered all studies to have low risk of other biasg.</p> </section> </section> <section id="CD009839-sec-0065"> <h3 class="title" id="CD009839-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD009839-tbl-0001"><b>Summary of findings for the main comparison</b> 5‐ASA compared with control (all trials) for prevention of recurrent diverticulitis</a> </p> <section id="CD009839-sec-0066"> <h4 class="title">Recurrence of diverticulitis</h4> <p>We included seven studies with a total of 1805 participants in the analysis for the primary outcome of recurrence of diverticulitis. We saw no statistically significant reduction in recurrence of diverticulitis with 5‐ASA versus control (31.3% vs 29.8%) with RR of 0.69 (95% CI 0.43 to 1.09; P = 0.11). We noted significant heterogeneity between studies (I<sup>2</sup> = 0.79; P &lt; 0.0001) (<a href="./references#CD009839-fig-0009" title="">Analysis 1.1</a>; <a href="#CD009839-fig-0004">Figure 4</a>). We rated the overall quality of evidence for the outcome recurrence of diverticulitis as very low (<a href="./full#CD009839-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD009839-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 5‐ASA vs all 'control' interventions, outcome: 6.1 Recurrence." data-id="CD009839-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 5‐ASA vs all 'control' interventions, outcome: 6.1 Recurrence.</p> </div> </div> </div> </section> <section id="CD009839-sec-0067"> <h4 class="title">Number of participants with adverse events</h4> <p>Only five studies provided sufficient data for analysis of the frequency of adverse events (<a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>; <a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). Among these, one trial reported no adverse event in either group (<a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>). The others reported no significant differences in the frequency of adverse events between 5‐ASA and control groups (67.8% vs 64.6%; RR 0.98, 95% CI 0.91 to 1.06; P = 0.63) and showed no significant heterogeneity (I<sup>2</sup> = 0; P = 0.50). We performed no further subgroup analyses for adverse events. See <a href="#CD009839-fig-0005">Figure 5</a> (<a href="./references#CD009839-fig-0010" title="">Analysis 1.2</a>). We rated the overall quality of evidence for this outcome as moderate (<a href="./full#CD009839-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD009839-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 5‐ASA vs control (all trials), outcome: 1.2 Participants with adverse events." data-id="CD009839-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 5‐ASA vs control (all trials), outcome: 1.2 Participants with adverse events. </p> </div> </div> </div> </section> <section id="CD009839-sec-0068"> <h4 class="title">Subgroup analyses</h4> <p>Subgroup analysis of study regimens revealed a significant difference in comparisons of 5‐ASA + antibiotics versus antibiotic monotherapy (RR 0.19, 95% CI 0.06 to 0.63) and 5‐ASA versus no therapy (RR 0.32, 95% CI 0.18 to 0.57) (<a href="./references#CD009839-fig-0011" title="">Analysis 2.1</a>; <a href="#CD009839-fig-0006">Figure 6</a>). However, we included only one small study in each of these subgroups (<a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>; <a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>). Analysis showed no significant differences for 5‐ASA + probiotics versus probiotic monotherapy (RR 0.50, 95% CI 0.05 to 4.94) in the Tursi study; for 5‐ASA versus placebo (RR 1.08, 95% CI 0.87 to 1.35) in the Parente, Stollman, and Raskin studies; and for 5‐ASA + probiotics versus placebo (RR 1.39, 95% CI 0.46 to 1.10) in the Stollman study (<a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>; <a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>). These subgroups showed significant heterogeneity (test for subgroup differences, I<sup>2</sup> = 0.82; P = 0.0002). </p> <div class="figure" id="CD009839-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 5‐ASA vs control ‐ subgroups by regimens and controls, outcome: 2.1 Recurrence." data-id="CD009839-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 5‐ASA vs control ‐ subgroups by regimens and controls, outcome: 2.1 Recurrence. </p> </div> </div> </div> <p>Methods used for confirmation of a diverticulitis before enrolment were not consistent across included trials. Four trials utilised CT scan or ultrasonography for primary diagnosis of diverticulitis (<a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). Subgroup analysis of studies that used CT or ultrasonography for primary diagnosis revealed no significant treatment effect (36.1% vs 31.3%; RR 1.11, 95% CI 0.80 to 1.35) (<a href="./references#CD009839-fig-0012" title="">Analysis 3.1</a>; <a href="#CD009839-fig-0007">Figure 7</a>). These studies showed no significant heterogeneity (I<sup>2</sup> = 0.18; P = 0.30).<br/> <br/> The remaining three trials used clinical assessment, laboratory indices, and colonoscopy to confirm the diagnosis (<a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>; <a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>; <a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>). Their pooled analysis favoured 5‐ASA for prevention of diverticulitis (7.8% vs 27.3%; RR 0.24, 95% CI 0.18 to 0.50) with no significant heterogeneity (I<sup>2</sup> = 0; P = 0.62). Differences between these two subgroups were statistically significant (I<sup>2</sup> = 0.95; P &lt; 0.000001). Furthermore, only three trials utilised CT scan for primary diagnosis of both diverticulitis and recurrence (<a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). Pooled analysis revealed no significant treatment effect (RR 1.07, 95% CI 0.81 to 1.40) (<a href="./references#CD009839-fig-0013" title="">Analysis 3.2</a>). Heterogeneity was not significant (I<sup>2</sup> = 45%; P = 0.16). </p> <div class="figure" id="CD009839-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 5‐ASA vs control ‐ subgroups based on method of diagnosis, outcome: 3.1 Recurrence based on CT for initial diagnosis." data-id="CD009839-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 5‐ASA vs control ‐ subgroups based on method of diagnosis, outcome: 3.1 Recurrence based on CT for initial diagnosis. </p> </div> </div> </div> <p>Subgroup analysis based on risk of bias revealed no significant differences between 5‐ASA and control groups among studies with unclear risk of bias (34.3% vs 28.2%; RR 0.93, 95% CI 0.59 to 1.49; test for heterogeneity I<sup>2</sup> = 77%; P = 0.001) or among studies with high risk of bias (17.5% vs 3.5%; RR 0.55, 95% CI 0.27 to 1.10; test for heterogeneity I<sup>2</sup> = 61%; P = 0.06) (<a href="#CD009839-fig-0008">Figure 8</a>). Results showed no statistical significant difference between the two subgroups (I<sup>2</sup> = 35%; P = 0.22). </p> <div class="figure" id="CD009839-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 5‐ASA vs control (double‐blind, placebo‐controlled trials), outcome: 7.1 Recurrence." data-id="CD009839-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 5‐ASA vs control (double‐blind, placebo‐controlled trials), outcome: 7.1 Recurrence. </p> </div> </div> </div> </section> <section id="CD009839-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>Results of this analysis were robust to the method of analysis. We used the random‐effects model for the overall analysis, for a pooled RR of 0.69 (95% CI 0.43 to 1.09). When we used a fixed‐effect model, the pooled RR was 0.90 (95% CI 0.77 to 1.06). Results remained non‐significant when we used the odds ratio (OR); the pooled OR was 0.60 (95% CI 0.32 to 1.13). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009839-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009839-sec-0070"></div> <p>Recurrence of diverticulitis after an initial episode is a common and important clinical problem. At present, no pharmacological agents have been approved for prevention of recurrent diverticulitis. Prophylactic surgery was previously recommended after two confirmed significant episodes of diverticulitis, but more recent guidelines advocate a more conservative approach (<a href="./references#CD009839-bbs2-0049" title="RaffertyJ , ShellitoP , Hyman NH: Standards Committee of the American Society of Colon and Rectal Surgeons. Practice parameters for sigmoid diverticulitis. DIseases of the Colon and Rectum2006;49:939‐44. ">Rafferty 2006</a>). This shift has been driven by the lack of evidence supporting routine elective colectomy among patients with recurrent diverticulitis (<a href="./references#CD009839-bbs2-0028" title="ChapmanJR , DozoisEJ , WolffBG . Diverticulitis: a progressive disease? Do multiple recurrences predict less favourable outcomes?. Annals of Surgery2006;243:876‐80. ">Chapman 2006</a>; <a href="./references#CD009839-bbs2-0030" title="CollinsD , WintersDC . Elective resection for diverticular disease: an evidence based review. World Journal of Surgery2008;32:2429‐33. ">Collins 2008</a>). Recently, even the use of antibiotics for diverticulitis has been questioned (<a href="./references#CD009839-bbs2-0027" title="ChabokA , PahlmanL , HjernF , HaapaniemiS , SmedhK , AVOD Study Group. Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. British Journal of Surgery2012;99:532‐9. ">Chabok 2012</a>). 5‐Aminosalicylic acid (ASA) offers the promise of modifying the underlying inflammation in patients with diverticular disease. This review evaluated available evidence for 5‐ASA for prevention of recurrence of diverticulitis. </p> <section id="CD009839-sec-0071"> <h3 class="title" id="CD009839-sec-0071">Summary of main results</h3> <p>We included seven randomised controlled trials (RCTs) in this review (<a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>; <a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>; <a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>; <a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). Four compared 5‐ASA versus placebo (<a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). One compared 5‐ASA in combination with probiotics versus probiotic monotherapy (<a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>). One compared 5‐ASA with an antibiotic (rifaximin) versus antibiotic monotherapy (<a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>). One compared 5‐ASA versus no therapy (<a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>). Stollman also reported a comparison of 5‐ASA plus probiotics versus placebo (<a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>). </p> <section id="CD009839-sec-0072"> <h4 class="title">Recurrent diverticulitis</h4> <p>The primary outcome of this review was prevention of recurrent diverticulitis. Overall, 5‐ASA was not superior to control interventions for prevention of diverticulitis. This result was robust to all sensitivity analyses. As expected, heterogeneity among the included studies was significant (I<sup>2</sup> = 0.79; P &lt; 0.0001). Control interventions used in trials that informed this review were varied (placebo, probiotic, antibiotic, and no therapy). Subgroup analysis based on treatment comparators revealed significant treatment effects with 5‐ASA + antibiotics versus antibiotic monotherapy (risk ratio (RR) 0.19, 95% confidence interval (CI) 0.06 to 0.63) and with 5‐ASA versus no therapy (RR 0.32, 95% CI 0.18 to 0.57), but each of these comparisons was based on only one small study. Both were open‐label trials with high or unclear risk of bias. </p> <p>Our review demonstrates the challenges associated with clinical research in diverticular disease. The pathogenesis of diverticulitis, a relatively common diagnosis, remains uncertain. This uncertainty focuses on whether infection or inflammation is the primary disturbance, and it affects the control therapies utilised in clinical trials. It is worth noting that the efficacy of both probiotics and antibiotics for preventing recurrence of diverticulitis remains unproven. </p> <p>Treatment effects can best be assessed in clinical trials that enrol a well‐defined, homogeneous, and responsive patient population. Among trials included in this review, methods used to diagnose index and recurrent episodes of diverticulitis were not consistent. The definition or diagnosis of a diverticulitis episode or recurrence was shown to be important in our review, as trials that required cross‐sectional imaging were less likely to demonstrate a treatment effect than trials that did not require cross‐sectional imaging. Four trials required use of computerised tomography (CT) scanning for primary diagnosis of diverticulitis (<a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). Pooled analysis of these trial results showed no significant treatment effect. Three trials required a CT scan for diagnosis of primary diverticulitis and recurrent events (<a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). These three trials best explored the objective of this review. Pooled analysis of results of these three trials revealed no significant treatment effect (RR 1.07, 95% CI 0.81 to 1.40). In sensitivity analyses, this result remained robust with use of odds ratios (ORs) and a fixed‐effect model. The three trials that did not use a CT scan for diagnosis of diverticulitis and relied mostly on clinical symptoms favoured 5‐ASA therapy (RR 0.30, 95% CI 0.18 to 0.50) (<a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>; <a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>; <a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>). It is possible to overestimate and misdiagnose cases of recurrence if only symptoms and laboratory indices are used (<a href="./references#CD009839-bbs2-0051" title="SarmaD , LongoWE , NDSG . Diagnostic imaging for diverticulitis. Journal of Clinical Gastroenterology2008;42:1139‐41. ">Sarma 2008</a>). We recommend that diagnoses of diverticulitis be confirmed by CT or ultrasonography in future clinical trials. </p> <p>Pooled analysis of results of clinical trials of diverticular disease is further challenged by the heterogeneous study design. Open‐label trials are common, and even the controlled trials included in this review were at risk of significant bias. Our overall results were consistent even after we removed studies identified as having high risk of bias. However, we assessed none of the included studies as having low risk of bias across all categories. Four of the included trials used a placebo‐controlled, double‐blind design (<a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). These studies constitute the best evidence regarding 5‐ASA therapy for diverticular disease, and each failed to demonstrate efficacy for prevention of recurrent diverticulitis. </p> <p>Many of the trials included in this review were small and had limited power to detect a treatment effect. PREVENT1 and PREVENT2 enrolled the largest patient cohorts and provided power calculations. Stollman reported that enrolment of 216 participants was required for adequate power but enrolled only 117 participants (<a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>). Therefore, this study was underpowered. The remaining studies reported no sample size calculation. </p> <p>Dosing regimens for 5‐ASA also varied across studies. Four studies administered 5‐ASA daily (<a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). The other three trials used cyclical regimens (<a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>; <a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>; <a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>). The total daily dose also varied across trials: Trepsi 1997 used 400 mg twice daily; Tursi 2002, 0.8 g three times daily for 7 days per month; Tursi 2007a, 2.25 g once daily for 10 days per month; Parente 2013, 0.8 g twice daily for 10 days per month; Stollman 2013, 2.4 g once daily; and PREVENT1 and PREVENT2, 1.2 g, 2.4 g, or 4.8 g once daily (<a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>; <a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>; <a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>; <a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). Available data were insufficient for review authors to explore a dose effect for treatment of diverticular disease. </p> <p>In summary, two individual studies have reported significant reductions in recurrence of diverticulitis with 5‐ASA therapy (Trespi evaluated 5‐ASA vs no therapy in 1999, and Tursi compared 5‐ASA plus antibiotic vs antibiotic alone in 2002), but the other five eligible studies have demonstrated no effect (<a href="./references#CD009839-bbs2-0005" title="TrespiE , CollaC , PanizzaP , PolinoMG , VenturiniA , BottaniG , et al. Therapeutic and prophylactic role of mesalazine (5‐ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow‐up results [&lt;Ruolo terapeutico e profilattico della mesalazina (5‐ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow‐up.&gt;]. Minerva Gastroenterologica e Dietologica1999;45(4):245‐52. TrespiE , PanizzaP , CollaC , BottaniG , DeVecchiP , MattiC . Efficacy of low dose mesalazine (5‐ASA) in the treatment of acute inflammation and prevention of complications inpatients with symptomatic diverticular disease [Efficacia della mesalazina (5‐ASA) a basse dosi nel trattamento della flogosi acuta e nella prevenzione delle complicanze in pazienti con malattia diverticolare sintomatica. Risultati preliminari]. Minerva Gastroenterologica e Dietologica1997;43(3):157‐62. ">Trespi 1999</a>; <a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>; <a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>; <a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). Pooled analysis revealed no overall statistically significant benefit. We have concluded that available trials included in this review do not support the use of 5‐ASA therapy for prevention of recurrent acute diverticulitis. </p> </section> <section id="CD009839-sec-0073"> <h4 class="title">Adverse events</h4> <p>We found 5‐ASA to be well tolerated. Five studies reported adverse event rates that could be analysed (<a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>; <a href="./references#CD009839-bbs2-0001" title="ParenteF , BargiggiaS , PradaA , BortoliA , GiacosaA , MontiC , et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double‐blind placebo‐controlled study of 24‐month duration. International Journal of Colorectal Disease2013;28:1423‐31. ">Parente 2013</a>; <a href="./references#CD009839-bbs2-0004" title="StollmanN , MagowanS , ShanahanF , QuigleyE . A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of Clinical Gastroenterology2013;47(7):621‐9. ">Stollman 2013 (DIVA)</a>; <a href="./references#CD009839-bbs2-0002" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT1)</a>; <a href="./references#CD009839-bbs2-0003" title="RaskinJ , KammM , JamalM , MarquezJ , MeizerE , SchoenR , et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology2014;147:793‐802. ">Raskin 2014 (PREVENT2)</a>). Total adverse events were no more common in the 5‐ASA arms than in the control arms. Results showed no significant heterogeneity (I<sup>2</sup> = 0; P = 0.50), but this finding should be interpreted with caution, as the I<sup>2</sup> test provides little power to reject the null hypothesis of homogeneity (I<sup>2</sup> = 0) when few studies are available, even if substantial heterogeneity is present (<a href="./references#CD009839-bbs2-0040" title="IoannidisJP , PatsopoulosNA , EvangelouE . Uncertainty in heterogeneity estimates in meta‐analyses. British Medical Journal2007;335(7626):914‐6. ">Loannidis 2007</a>). </p> </section> </section> <section id="CD009839-sec-0074"> <h3 class="title" id="CD009839-sec-0074">Overall completeness and applicability of evidence</h3> <p>This review sought to evaluate the efficacy of 5‐ASA in preventing recurrence of diverticulitis. We were prepared to include studies from any source, regardless of publication status or language. Of the originally 23 eligible studies for inclusion, we were able to retrieve full manuscripts for all but two studies. These two were published only in abstract form and provided insufficient data for analysis (<a href="#CD009839-fig-0001">Figure 1</a>).<br/> Pooled results of included studies could not establish a role for 5‐ASA for this indication, and it is unlikely that these two abstracts would change our overall results. We believe that this review accurately reflects available evidence for 5‐ASA for prevention of recurrent diverticulitis. </p> <p>We were not able to analyse adverse effects in all included trials. In addition, we could analyse only total adverse effects. as the data reported were insufficient to permit any substantive evaluation of individual adverse events. We concluded that in trials included in this review, 5‐ASA was well tolerated and performed similarly to placebo. However, we must concede that two of the included trials did not provide analysable data regarding adverse events. What effect this had, if any, on our final results remains uncertain. </p> <p>The present standard of medical care for diverticulitis involves antibiotics in the acute setting but no subsequent therapy to prevent recurrence and/or complications. The evidence presented here does not call for any change in this treatment paradigm. </p> </section> <section id="CD009839-sec-0075"> <h3 class="title" id="CD009839-sec-0075">Quality of the evidence</h3> <p>Overall, the quality of evidence for the outcome recurrence of diverticulitis is very low owing to study limitations and significant heterogeneity (<a href="./full#CD009839-tbl-0001">summary of findings Table for the main comparison</a>). We included in this review only seven randomised controlled trials that enrolled a total of 1805 participants with diverticulitis. We considered four of seven studies to be at high risk of bias and noted that heterogeneity among studies was significant. The confidence interval does not exclude appreciable benefit or no difference. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change this estimate. </p> <p>The overall quality of evidence for the outcome number of participants with adverse events is moderate. Only five studies with 1421 participants contributed data to this outcome. Three of five studies were at high risk of bias. Results showed no significant heterogeneity for the outcome adverse events but should be interpreted with caution because included studies were few. </p> </section> <section id="CD009839-sec-0076"> <h3 class="title" id="CD009839-sec-0076">Potential biases in the review process</h3> <p>A potential limitation of this review is that included studies used various methods to diagnose a diverticulitis event. This may make direct comparison of these trial results difficult. </p> <p>We did not explore publication bias in this review because we included only seven studies for the primary outcome and five for the secondary outcome. Application of funnel plot asymmetry tests to detect publication bias is inappropriate or is not meaningful for this review, as we included only a few studies for the outcomes reported in this review (<a href="./references#CD009839-bbs2-0040" title="IoannidisJP , PatsopoulosNA , EvangelouE . Uncertainty in heterogeneity estimates in meta‐analyses. British Medical Journal2007;335(7626):914‐6. ">Loannidis 2007</a>). </p> </section> <section id="CD009839-sec-0077"> <h3 class="title" id="CD009839-sec-0077">Agreements and disagreements with other studies or reviews</h3> <p>This review is consistent with other published systematic reviews in this area. In 2011, Maconi published a review of medical therapy for both treatment of symptoms of diverticular disease and prevention of recurrent diverticulitis (<a href="./references#CD009839-bbs2-0041" title="MaconiG , BarbaraG , BosettiC , CuomoR , AnnibaleB . Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review. Diseases of Colon and Rectum2011;54(10):1326‐38. ">Maconi 2011</a>). These review authors concluded that medical therapy (including 5‐ASA) did not improve symptoms, but that its role in preventing recurrent diverticulitis needed to be further defined. In 2012, Unlu published a review of medical therapy for prevention of recurrent diverticulitis (<a href="./references#CD009839-bbs2-0062" title="UnluC , DanielsL , VrouenraetsBC , BoermeesterMA . Systematic review of medical therapy to prevent recurrent diverticulitis. International Journal of Colorectal Disease2012;27(9):1131‐6. ">Unlu 2012</a>). These review authors identified three trials, two of which evaluated 5‐ASA (<a href="./references#CD009839-bbs2-0006" title="TursiA , BrandimarteG , DaffinaR . Long‐term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Digestive and Liver Disease2002;34:510‐5. ">Tursi 2002</a>; <a href="./references#CD009839-bbs2-0007" title="TursiA , GiovanniB , Marco GiorgettiG , EliseiW , AielloF . Balsalazide and/or high potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International Journal of Colorectal Disease2007;22:1103‐8. ">Tursi 2007a</a>). They concluded that the evidence supporting medical therapy was of low quality, but that 5‐ASA was the most promising of the available medical therapies. Tursi published a review of recent advances in the management of colonic diverticulitis, wherein he concluded that the evidence for 5‐ASA for preventing recurrence was promising, but that dosing and schedules remained unclear (<a href="./references#CD009839-bbs2-0060" title="TursiA . Advances in the management of colonic diverticulitis. Canadian Medical Association Journal2012;184(13):1470‐6. ">Tursi 2012</a>). This same review author later concluded, in a review on new medical strategies for management of acute diverticulitis, that evidence on effective strategies for prevention of recurrence is lacking (<a href="./references#CD009839-bbs2-0061" title="TursiA . New medical strategies for the management of acute diverticulitis. Expert Review of Gastroenterology &amp; Hepatology2015;9(10):1293‐304. ">Tursi 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009839-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009839-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009839-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009839-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 5‐ASA vs all 'control' interventions, outcome: 6.1 Recurrence." data-id="CD009839-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 5‐ASA vs all 'control' interventions, outcome: 6.1 Recurrence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 5‐ASA vs control (all trials), outcome: 1.2 Participants with adverse events." data-id="CD009839-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 5‐ASA vs control (all trials), outcome: 1.2 Participants with adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 5‐ASA vs control ‐ subgroups by regimens and controls, outcome: 2.1 Recurrence." data-id="CD009839-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 5‐ASA vs control ‐ subgroups by regimens and controls, outcome: 2.1 Recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 5‐ASA vs control ‐ subgroups based on method of diagnosis, outcome: 3.1 Recurrence based on CT for initial diagnosis." data-id="CD009839-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 5‐ASA vs control ‐ subgroups based on method of diagnosis, outcome: 3.1 Recurrence based on CT for initial diagnosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 5‐ASA vs control (double‐blind, placebo‐controlled trials), outcome: 7.1 Recurrence." data-id="CD009839-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 5‐ASA vs control (double‐blind, placebo‐controlled trials), outcome: 7.1 Recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 5‐ASA vs control (all trials), Outcome 1 Recurrence." data-id="CD009839-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 5‐ASA vs control (all trials), Outcome 1 Recurrence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references#CD009839-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 5‐ASA vs control (all trials), Outcome 2 Number of participants with adverse events." data-id="CD009839-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 5‐ASA vs control (all trials), Outcome 2 Number of participants with adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references#CD009839-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 5‐ASA vs control ‐ subgroups based on regimens, Outcome 1 Recurrence." data-id="CD009839-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 5‐ASA vs control ‐ subgroups based on regimens, Outcome 1 Recurrence.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references#CD009839-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 5‐ASA vs control ‐ subgroups based on method of diagnosis, Outcome 1 Recurrence based on CT for initial diagnosis." data-id="CD009839-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 5‐ASA vs control ‐ subgroups based on method of diagnosis, Outcome 1 Recurrence based on CT for initial diagnosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references#CD009839-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 5‐ASA vs control ‐ subgroups based on method of diagnosis, Outcome 2 Recurrence based on CT scan for all events." data-id="CD009839-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 5‐ASA vs control ‐ subgroups based on method of diagnosis, Outcome 2 Recurrence based on CT scan for all events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references#CD009839-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009839-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/urn:x-wiley:14651858:media:CD009839:CD009839-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_t/tCD009839-CMP-004-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 5‐ASA vs control ‐ subgroup analyses based on risk of bias, Outcome 1 Recurrence." data-id="CD009839-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 5‐ASA vs control ‐ subgroup analyses based on risk of bias, Outcome 1 Recurrence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references#CD009839-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/media/CDSR/CD009839/image_n/nCD009839-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009839-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">5‐ASA compared with control (all trials) for prevention of recurrent diverticulitis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>5‐ASA compared with control (all trials) for prevention of recurrent diverticulitis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with the need for management of diverticulitis<br/> <b>Setting:</b> hospital<br/> <b>Intervention:</b> 5‐ASA<br/> <b>Comparison:</b> placebo, probiotic, antibiotic </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control (all trials)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐ASA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrence of diverticulitis<br/> Follow‐up: range 1 to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.69<br/> (0.43 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1805<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 100<br/> (13 to 33) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number of participants with adverse events (epigastric pain, nausea, diarrhoea)<br/> Follow‐up: range 1 to 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/> (0.91 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1421<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 100<br/> (59 to 68) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> 5‐ASA: 5‐aminosalicylic acid; CI: confidence interval; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias (four of seven studies were assessed to be at high risk of bias). </p> <p><sup>b</sup>The confidence interval does not exclude an appreciable benefit or no difference. </p> <p><sup>c</sup>Downgraded one level for inconsistency (significant heterogeneity of results might be explained by control regimens and methods of diagnosis). </p> <p><sup>d</sup>The confidence interval excludes appreciable benefit or harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">5‐ASA compared with control (all trials) for prevention of recurrent diverticulitis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/full#CD009839-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009839-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">5‐ASA vs control (all trials)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.43, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">5‐ASA vs control (all trials)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references#CD009839-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009839-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">5‐ASA vs control ‐ subgroups based on regimens</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.46, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 5‐ASA + probiotics vs probiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 4.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 5‐ASA + antibiotics vs antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.06, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 5‐ASA vs no therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.18, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 5‐ASA vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.87, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 5‐ASA + probiotics vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.50, 3.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">5‐ASA vs control ‐ subgroups based on regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references#CD009839-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009839-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">5‐ASA vs control ‐ subgroups based on method of diagnosis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recurrence based on CT for initial diagnosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.43, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 CT scan/ultrasound primary diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.89, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.18, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Recurrence based on CT scan for all events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.43, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 CT scan for primary diagnosis and recurrence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.81, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.18, 1.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">5‐ASA vs control ‐ subgroups based on method of diagnosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references#CD009839-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009839-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">5‐ASA vs control ‐ subgroup analyses based on risk of bias</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.43, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies at unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.59, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Studies at high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.27, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">5‐ASA vs control ‐ subgroup analyses based on risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009839.pub2/references#CD009839-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009839.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009839-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009839-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD009839-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD009839-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009839-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009839\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009839\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009839\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009839\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009839\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009839.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009839.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009839.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009839.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009839.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729575093"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009839.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729575097"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009839.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee03b3e2bbd65',t:'MTc0MDcyOTU3NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 